The Role of Chemotherapy in Patients With HER2-Negative Isolated Locoregional Recurrence of Breast Cancer: A Multicenter Retrospective Cohort Study
Open Access
- 5 March 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Abstract
Background: The role of chemotherapy for isolated locoregional recurrence (iLRR) of breast cancer has not been firmly established after local therapies.Methods: We performed a multicenter, retrospective analysis to evaluate the clinical implications of chemotherapy in breast cancer patients with HER2-negative iLRR.Results: Of a total of 277 patients, 146 (52.7%) received chemotherapy for iLRR. Median follow-up duration was 56.1 months. Eighty-six (31.0%) patients had luminal B-like and 100 (36.1%) had TNBC iLRR. There was a trend of longer disease free survival (DFS) in the chemotherapy group (4-year DFS: 70.4 vs. 59.5%, HR = 0.68, 95% CI 0.45–1.02, log-rank p = 0.059). When adjusted with clinically relevant factors, DFS was significantly prolonged with chemotherapy (adjusted HR = 0.61, 95% CI 0.40–0.94, p = 0.023). Subgroup analyses for DFS showed patients with disease free interval (DFI) p = 0.018; adjusted HR = 0.51, p = 0.005, respectively). Regarding the molecular subtypes, a longer DFS with chemotherapy was observed both in luminal B-like (4-year DFS: 77.8 vs. 55.0%, HR = 0.51, 95% CI 0.27–0.99, log-rank p = 0.048) and in TNBC patients (4-year DFS: 61.9 vs. 42.8%, HR = 0.49, 95% CI 0.24–1.02, log-rank p = 0.056), but not in luminal A-like.Conclusions: The chemotherapy for iLRR of breast cancer should be individualized for each patient, considering DFI, prior chemotherapy, and molecular subtypes.Keywords
Funding Information
- Korea University Guro Hospital (O2001111, O2001151)
This publication has 20 references indexed in Scilit:
- Management of Isolated Locoregional Recurrences in Breast Cancer: A Review of Local and Systemic ModalitiesClinical Breast Cancer, 2017
- 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)Annals of Oncology, 2016
- Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trialThe Lancet Oncology, 2014
- Molecular and Cellular Heterogeneity in Breast CancerThe American Journal of Pathology, 2013
- Biomarkers for the clinical management of breast cancer: International perspectiveInternational Journal of Cancer, 2012
- Management of locoregional recurrence of breast cancerBreast Cancer, 2010
- Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Patients Treated by Breast-Conserving Therapy in Five National Surgical Adjuvant Breast and Bowel Project Protocols of Node-Negative Breast CancerJournal of Clinical Oncology, 2009
- Ipsilateral Breast Tumor Recurrence: Is There Any Evidence for Benefit of Further Systemic Therapy?The Breast Journal, 2009
- Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Five National Surgical Adjuvant Breast and Bowel Project Node-Positive Adjuvant Breast Cancer TrialsJournal of Clinical Oncology, 2006
- Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM)European Journal of Cancer, 1999